β1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 1, 2006, Pages 23-32

  Liu, Jie ^a   Liu, Zhao Qian ^a   Yu, Bang Ning ^a   Xu, Fang Hua ^a   Mo, Wei ^a   Zhou, Gan ^a   Liu, Ying Zi ^a   Li, Qing ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR; GLYCINE; METOPROLOL; SERINE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; GENOTYPE; HEART RATE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD PRESSURE; CHINA; GENETIC POLYMORPHISM; GENETICS; HYPERTENSION; MIDDLE AGED; PHARMACOGENETICS;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; CHINA; FEMALE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, ADRENERGIC, BETA;

EID: 33745353777     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.03.004     Document Type: Article

References (32)

1. Small K.M., McGraw D.W., and Liggett S.B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43 (2003) 381-411
2. 1-adrenergic receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
3. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
4. 1-adrenoceptor blockade by propranolol. J Cardiovasc Pharmacol 6 (1984) 361-364
5. Venter C.P., Joubert P.H., and Strydom W.J. The relevance of ethnic differences in hemodynamic responses to the head-up tilt manoeuvre to clinical pharmacological investigations. J Cardiovasc Pharmacol 7 (1985) 1009-1010
6. Zhou H.H., Koshakji R.P., Silberstein D.J., Wilkinson G.R., and Wood A.J.J. Racial differences in drug response. altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 320 (1989) 565-570
7. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension: II. Results of longterm therapy. JAMA 248 (1982) 2004-2011
8. Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., et al., The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 328 (1993) 914-921
9. 1-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 26 (1979) 181-186
10. Feely J., Crooks J., and Stevenson I.H. The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration. Br J Clin Pharmacol 12 (1981) 73-78
11. Lennard M.S., Silas J.H., Freestone S., Ramsay L.E., Tucker G.T., and Woods H.F. Oxidation phenotype. a major determinant of metoprolol metabolism and response. N Engl J Med 307 (1982) 1158-1160
12. Vesell E.S. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 40 (2000) 930-938
13. Frielle T., Collins S., Daniel K.W., Caron M., Lefkowitz R.J., and Kobilka B.K. Cloning of the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci U S A 84 (1987) 7920-7924
14. Yang-Feng T.L., Xue F., Zhong W., Cotecchia S., Frielle T., Francke U., et al. Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci U S A 87 (1990) 1516-1520
15. 1-adrenoceptor gene variations. a role in idiopathic dilated cardiomyopathy?. J Mol Med 78 (2000) 87-93
16. 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39 (2002) 155-160
17. 1-adrenergic receptor. J Biol Chem 274 (1999) 12670-12674
18. 1-adrenergic receptor polymorphisms. analysis of c145A→G and c1165G→C. Hum Mut 14 (1999) 271
19. 1-adrenoceptor. identification and rapid screening assay. [letter]. Lancet 353 (1999) 897
20. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 11 (2001) 191-197
21. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 31 (1999) 1025-1032
22. 1-adrenergic receptor polymorphisms and linkage disequilibrium. [abstract]. Clin Pharmacol Ther 71 (2002) P70
23. Sandilands A., Yeo G., Brown M.J., and O'Shaughnessy K.M. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. Pharmacogenetics 14 (2004) 343-349
24. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74 (2003) 44-52
25. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning. a laboratory manual. 2nd ed (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY)
26. Garcia-Barcelo M., Chow L.Y., Chiu H.F., Wing Y.K., Lee D.T., Lam K.L., et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 46 (2000) 18-23
27. Jiang Z., Ma H., and Zhang L. Clinical observation of metoprolol in treatment of essential hypertension. Chin J Hypertension 2 (1994) 125-126
28. Rozas J., and Rozas R. DnaSP version 3. An integrated program for molecular population genetics and molecular evolution analysis. Bioinformatics 15 (1999) 174-175
29. Kralberg B.E., and Tolagen K. Different antihypertensive effect of β-blocking drugs in low and normal-high renin hypertension. Am J Med 60 (1976) 891-896
30. Liu J., Liu Z.Q., Tan Z.R., Chen X.P., Wang L.S., Zhou G., et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74 (2003) 372-379
31. O'Shaughnessy K.M., Fu B., Dickerson C., Thurston D., and Brown M.J. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci 99 (2000) 233-238
32. 1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther 74 (2003) 366-371